ArticleCell cycle (Georgetown, Tex.)2012
Selective blockade of tumor angiogenesis.
Article in Cell cycle (Georgetown, Tex.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.Journal for immunotherapy of cancer · 2019Article
- Increased Soluble CMG2 Serum Protein Concentration is Associated with the Progression of Prostate Carcinoma.Cancers · 2019Article
- TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo.PloS one · 2019Article
- Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.The Journal of clinical investigation · 2018Article
- Seneca Valley Virus Exploits TEM8, a Collagen Receptor Implicated in Tumor Growth.Frontiers in oncology · 2018Review
- Microenvironmental regulation of tumour angiogenesis.Nature reviews. Cancer · 2017Review
- Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface.Oncotarget · 2016Article
- Tumour endothelial marker-8 in wound healing and its impact on the proliferation and migration of keratinocytes.International journal of molecular medicine · 2016Article
- Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates.Disease markers · 2016Review
- Proline metabolism and cancer: emerging links to glutamine and collagen.Current opinion in clinical nutrition and metabolic care · 2015Review
- Immuno-PET imaging of tumor endothelial marker 8 (TEM8).Molecular pharmaceutics · 2014Article
- Vasohibin-2 modulates tumor onset in the gastrointestinal tract by normalizing tumor angiogenesis.Molecular cancer · 2014Article
- Mutations in ANTXR1 cause GAPO syndrome.American journal of human genetics · 2013Article
- Gene expression analysis reveals marked differences in the transcriptome of infantile hemangioma endothelial cells compared to normal dermal microvascular endothelial cells.Vascular cell · 2013Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Blocking tumor angiogenesis is an important goal of cancer therapy, but clinically approved anti-angiogenic agents suffer from limited efficacy and adverse side effects, fueling the need to identify alternative angiogenesis regulators. Tumor endothelial marker 8 (TEM8) is a highly conserved cell surface receptor overexpressed on human tumor vasculature. Genetic disruption of Tem8 in mice revealed that TEM8 is important for promoting tumor angiogenesis and tumor growth but dispensable for normal development and wound healing. The induction of TEM8 in cultured endothelial cells by nutrient or growth factor deprivation suggests that TEM8 may be part of a survival response pathway that is activated by tumor microenvironmental stress. In preclinical studies, antibodies targeted against the extracellular domain of TEM8 inhibited tumor angiogenesis and blocked the growth of multiple human tumor xenografts. Anti-TEM8 antibodies augmented the activity of other anti-angiogenic agents, vascular targeting agents and conventional chemotherapeutic agents and displayed no detectable toxicity. Thus, anti-TEM8 antibodies provide a promising new tool for selective blockade of neovascularization associated with cancer and possibly other angiogenesis-dependent diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.